Travere director granted shares and stock options

Travere Therapeutics, Inc. director Ruth Williams Brinkley received an automatic equity grant under the company’s 2018 Equity Incentive Plan pursuant to its non-employee director compensation program.

Rhea-AI Filing Summary

Travere Therapeutics, Inc. director Ruth Williams Brinkley received an automatic equity grant under the company’s 2018 Equity Incentive Plan pursuant to its non-employee director compensation program. The award includes 4,000 shares of common stock and stock options for 12,000 shares at an exercise price of $42.26 per share.

The equity award vests over a one-year period. The stock options become exercisable beginning on May 19, 2027 and expire on May 19, 2036. Following the stock grant, Brinkley directly holds 29,750 shares of Travere Therapeutics common stock.

Insider Trade Summary

Grant/Award: 16,000 shares

Grant/Award 2 txns

Insider Williams Brinkley Ruth

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	12,000	$0.00	$0.00
Grant/Award	Common Stock	4,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 12,000 contracts (Direct); Common Stock — 29,750 shares (Direct)

Footnotes (2)

1. F1. Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.
2. F2. The equity award vests over a one year period.

Key Figures

Stock grant: 4,000 shares Option grant size: 12,000 options Option exercise price: $42.26/share +3 more

6 metrics

Stock grant 4,000 shares Automatic common stock award to director on May 19, 2026

Option grant size 12,000 options Stock option (right to buy) granted on May 19, 2026

Option exercise price $42.26/share Conversion or exercise price for 12,000 stock options

Shares held after grant 29,750 shares Total common stock directly owned after the 4,000-share award

Option exercisability date May 19, 2027 First exercisability date for 12,000 stock options

Option expiration date May 19, 2036 Expiration of the 12,000-share stock option grant

Key Terms

Automatic equity grant, 2018 Equity Incentive Plan, non-employee director compensation program, Stock option (right to buy)

4 terms

Automatic equity grant financial

"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."

2018 Equity Incentive Plan financial

"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."

non-employee director compensation program financial

"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."

Stock option (right to buy) financial

"Stock option (right to buy) reported as a derivative security transaction on May 19, 2026."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity awards were reported for TVTX director Ruth Williams Brinkley?

Ruth Williams Brinkley received 4,000 Travere Therapeutics common shares and stock options for 12,000 shares. These were automatic equity grants under the 2018 Equity Incentive Plan, issued through the non-employee director compensation program as reported in the Form 4.

What is the exercise price and term of the new TVTX stock options?

The reported stock options have an exercise price of $42.26 per share and cover 12,000 shares. They become exercisable on May 19, 2027 and expire on May 19, 2036, giving the director a long-dated equity incentive position.

How many Travere Therapeutics shares does the director hold after this Form 4?

After receiving the 4,000-share stock grant, Ruth Williams Brinkley directly holds 29,750 shares of Travere Therapeutics common stock. This figure reflects her position immediately following the reported non-derivative equity award on May 19, 2026.

How do the TVTX equity awards for Ruth Williams Brinkley vest?

The equity award reported for Ruth Williams Brinkley vests over a one-year period. This applies to the automatic grant made under Travere Therapeutics’ 2018 Equity Incentive Plan pursuant to the company’s non-employee director compensation program, aligning compensation with short-term board service.

Are the reported Travere Therapeutics equity awards open-market purchases or compensation grants?

The reported transactions are compensation-related grants, not open-market purchases. Both the 4,000-share common stock award and the 12,000-share stock option grant were automatic equity grants under the 2018 Equity Incentive Plan for a non-employee director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/21/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Williams Brinkley Ruth

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DRIVE, SUITE 300

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		A		4,000(1)(2)	A	$0	29,750	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$42.26	05/19/2026		A		12,000(1)		05/19/2027(2)	05/19/2036	Common Stock	12,000	$0	12,000	D

Explanation of Responses:

1. Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

2. The equity award vests over a one year period.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)